Mochida Pharmaceutical Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mochida Pharmaceutical Co., Ltd.
Private Company Edition: Last year set a high bar for venture capital, but this year is starting strong. Recent VC mega-deals include $500m for EQRx and $230m-plus for Tessera Therapeutics. Also, BioGeneration Ventures closed a €140m ($170.2m) fund and NewAmsterdam raised a $196m series A.
Top 100 Review: The Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19
2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.
Fresh from announcing the €642m ($762m) divestment of its Thrombosis business in Europe to Mylan, Aspen Pharmacare management walked investors through its full-year earnings, explaining in detail the company’s ambitions to focus on emerging markets.
Aspen Pharmacare last week announced the sale of its thrombosis business in Europe to Mylan for €642m ($762m). CEO Stephen Saad faced investors to detail the rationale for the US firm and what the planned transaction means for Aspen, including its material debt pile.
- Medical Devices
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
- Mochida Pharmaceutical Plant Co., Ltd.
- Mochida Healthcare Co., Ltd.